Nicholas D Socci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6345567/publications.pdf

Version: 2024-02-01

117 30,768 71 117
papers citations h-index g-index

121 121 121 45335
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunology Research, 2022, 10, 303-313.	1.6	1
2	TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. Journal of Experimental Medicine, 2022, 219, .	4.2	64
3	Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. Cancer Immunology, Immunotherapy, 2021, 70, 1189-1202.	2.0	7
4	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Medicine, 2021, 13, 96.	3.6	26
5	Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clinical Cancer Research, 2021, 27, 4003-4011.	3.2	7
6	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. Clinical Cancer Research, 2021, 27, 1516-1525.	3.2	6
7	The Evolutionary Origins of Recurrent Pancreatic Cancer. Cancer Discovery, 2020, 10, 792-805.	7.7	71
8	Eomes identifies thymic precursors of self-specific memory-phenotype CD8+ T cells. Nature Immunology, 2020, 21, 567-577.	7.0	55
9	Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival. Cancer Research, 2020, 80, 2461-2471.	0.4	22
10	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	13.7	295
11	Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4889-4899.	1.8	26
12	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncology, 2019, 5, 471.	3.4	426
13	Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A. Oncotarget, 2019, 10, 6152-6167.	0.8	14
14	Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discovery, 2018, 8, 174-183.	7.7	275
15	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical Cancer Research, 2018, 24, 1965-1973.	3.2	85
16	Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Research, 2018, 78, 4642-4657.	0.4	60
17	Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers. Journal of Clinical Investigation, 2018, 128, 4086-4097.	3.9	49
18	Epigenetic Drug Treatment Induces Presentation of New Class of Non-Exonic, Cryptic Neoantigens in Acute Myeloid Leukemia Cells. Blood, 2018, 132, 2717-2717.	0.6	2

#	Article	IF	Citations
19	PGBD5 promotes site-specific oncogenic mutations in human tumors. Nature Genetics, 2017, 49, 1005-1014.	9.4	69
20	miR-193b–Regulated Signaling Networks Serve as Tumor Suppressors in Liposarcoma and Promote Adipogenesis in Adipose-Derived Stem Cells. Cancer Research, 2017, 77, 5728-5740.	0.4	50
21	Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. European Urology, 2017, 71, 405-414.	0.9	173
22	Dendritic Cells Coordinate the Development and Homeostasis of Organ-Specific Regulatory T Cells. Immunity, 2016, 44, 847-859.	6.6	93
23	Aire Enforces Immune Tolerance by Directing Autoreactive T Cells into the Regulatory T Cell Lineage. Immunity, 2016, 44, 1102-1113.	6.6	173
24	Mutational landscape of <i>EGFR-</i> , <i>MYC-</i> , and <i>Kras-</i> driven genetically engineered mouse models of lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6409-E6417.	3.3	158
25	Integrin- $\hat{l}\pm10$ Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma. Cancer Discovery, 2016, 6, 1148-1165.	7.7	62
26	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nature Biotechnology, 2016, 34, 155-163.	9.4	634
27	Near universal detection of alterations in <scp><i>CTNNB1</i></scp> and <scp>Wnt</scp> pathway regulators in desmoidâ€type fibromatosis by wholeâ€exome sequencing and genomic analysis. Genes Chromosomes and Cancer, 2015, 54, 606-615.	1.5	138
28	Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget, 2015, 6, 36041-36052.	0.8	103
29	miR-182 Is Largely Dispensable for Adaptive Immunity: Lack of Correlation between Expression and Function. Journal of Immunology, 2015, 194, 2635-2642.	0.4	31
30	Inducible in vivo genome editing with CRISPR-Cas9. Nature Biotechnology, 2015, 33, 390-394.	9.4	429
31	Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations. Cancer Research, 2015, 75, 3713-3719.	0.4	48
32	The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPKÂsignalling. Nature Cell Biology, 2015, 17, 81-94.	4.6	97
33	Recurrent Mutations in CCND3 Confer Clinical Resistance to FLT3 Inhibitors. Blood, 2015, 126, 677-677.	0.6	4
34	Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PLoS ONE, 2015, 10, e0134731.	1.1	38
35	MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget, 2015, 6, 8226-8243.	0.8	107
36	High-Depth, Targeted, Next Generation Sequencing Identifies Novel Genetic Alterations in Cutaneous T-Cell Lymphoma. Blood, 2015, 126, 1485-1485.	0.6	1

#	Article	IF	CITATIONS
37	Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma. Blood, 2015, 126, 3655-3655.	0.6	1
38	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nature Genetics, 2014, 46, 595-600.	9.4	152
39	Characterization of a set of tumor suppressor microRNAs in T cell acute lymphoblastic leukemia. Science Signaling, 2014, 7, ra111.	1.6	36
40	Synthetic Lethality in ATM-Deficient <i>RAD50</i> Hutant Tumors Underlies Outlier Response to Cancer Therapy. Cancer Discovery, 2014, 4, 1014-1021.	7.7	114
41	Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. Clinical Cancer Research, 2014, 20, 1955-1964.	3.2	208
42	Genome-wide mapping of the distribution of CarD, RNAP $\ddot{l}f$ A, and RNAP \hat{l}^2 on the Mycobacterium smegmatis chromosome using chromatin immunoprecipitation sequencing. Genomics Data, 2014, 2, 110-113.	1.3	14
43	Novel Imidazoline Antimicrobial Scaffold That Inhibits DNA Replication with Activity against Mycobacteria and Drug Resistant Gram-Positive Cocci. ACS Chemical Biology, 2014, 9, 2572-2583.	1.6	17
44	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 1226-1231.	9.4	270
45	Aire-Dependent Thymic Development of Tumor-Associated Regulatory T Cells. Science, 2013, 339, 1219-1224.	6.0	282
46	Next-Generation Sequencing Suggests Complex, Heterogeneous Pathogenesis In Peripheral T-Cell Lymphoma Unspecified. Blood, 2013, 122, 843-843.	0.6	2
47	Copy Number Losses Define Subgroups of Dedifferentiated Liposarcoma with Poor Prognosis and Genomic Instability. Clinical Cancer Research, 2012, 18, 1334-1340.	3.2	59
48	Intestinal Domination and the Risk of Bacteremia in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases, 2012, 55, 905-914.	2.9	779
49	Genome Sequencing Identifies a Basis for Everolimus Sensitivity. Science, 2012, 338, 221-221.	6.0	681
50	Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. New England Journal of Medicine, 2012, 366, 1079-1089.	13.9	1,688
51	Systematic screen for tyrosine kinase rearrangements identifies a novel ⟨i⟩C6orf2O4â€PDGFRB⟨ i⟩ fusion in a patient with recurrent Tâ€ALL and an associated myeloproliferative neoplasm. Genes Chromosomes and Cancer, 2012, 51, 54-65.	1.5	23
52	Germline mutations in BAP1 predispose to melanocytic tumors. Nature Genetics, 2011, 43, 1018-1021.	9.4	662
53	Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling. Science Translational Medicine, 2011, 3, 90ra59.	5.8	457
54	A Hierarchical Combination of Factors Shapes the Genome-wide Topography of Yeast Meiotic Recombination Initiation. Cell, 2011, 144, 719-731.	13.5	520

#	Article	IF	Citations
55	The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma. Cell, 2011, 147, 554-564.	13.5	151
56	miR-371-3 Expression Predicts Neural Differentiation Propensity in Human Pluripotent Stem Cells. Cell Stem Cell, 2011, 8, 695-706.	5.2	126
57	Small RNA Sequencing and Functional Characterization Reveals MicroRNA-143 Tumor Suppressor Activity in Liposarcoma. Cancer Research, 2011, 71, 5659-5669.	0.4	106
58	Frequent Alterations and Epigenetic Silencing of Differentiation Pathway Genes in Structurally Rearranged Liposarcomas. Cancer Discovery, 2011, 1, 587-597.	7.7	108
59	Treatment with 5-Azacytidine Accelerates Acute Promyelocytic Leukemia Leukemogenesis in a Transgenic Mouse Model. Genes and Cancer, 2011, 2, 160-165.	0.6	2
60	DNA Methylation of the First Exon Is Tightly Linked to Transcriptional Silencing. PLoS ONE, 2011, 6, e14524.	1.1	503
61	Integrative Genomic Profiling of Human Prostate Cancer. Cancer Cell, 2010, 18, 11-22.	7.7	3,151
62	Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature, 2010, 464, 436-440.	13.7	245
63	Identification of DOK genes as lung tumor suppressors. Nature Genetics, 2010, 42, 216-223.	9.4	105
64	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics, 2010, 42, 715-721.	9.4	642
65	Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. Journal of Clinical Investigation, 2010, 120, 4332-4341.	3.9	756
66	<i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma. Cancer Research, 2010, 70, 6891-6901.	0.4	41
67	Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Research, 2010, 38, 6985-6996.	6.5	39
68	Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16759-16765.	3.3	567
69	A Differentiation-Based MicroRNA Signature Identifies Leiomyosarcoma as a Mesenchymal Stem Cell-Related Malignancy. American Journal of Pathology, 2010, 177, 908-917.	1.9	71
70	Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunology, Immunotherapy, 2009, 58, 339-349.	2.0	85
71	BAC Transgenesis in Human Embryonic Stem Cells as a Novel Tool to Define the Human Neural Lineage. Stem Cells, 2009, 27, 521-532.	1.4	75
72	Genome-Wide Analysis of DNA Methylation Patterns Reveals Dynamic Epigenetic Regulation of the AML Genome After Decitabine Treatment Blood, 2009, 114, 591-591.	0.6	1

#	Article	IF	Citations
73	Enriched motor neuron populations derived from bacterial artificial chromosome-transgenic human embryonic stem cells. Clinical Neurosurgery, 2009, 56, 125-32.	0.2	3
74	High-Throughput Screening Assay for the Identification of Compounds Regulating Self-Renewal and Differentiation in Human Embryonic Stem Cells. Cell Stem Cell, 2008, 2, 602-612.	5.2	211
75	A Developmental Model of Sarcomagenesis Defines a Differentiation-Based Classification for Liposarcomas. American Journal of Pathology, 2008, 172, 1069-1080.	1.9	65
76	Cellular program controlling the recovery of adipose tissue mass: An <i>in vivo</i> imaging approach. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 12985-12990.	3.3	34
77	Human ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. Genes and Development, 2008, 22, 152-165.	2.7	604
78	Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2008, 14, 3204-3215.	3.2	233
79	Functional Copy-Number Alterations in Cancer. PLoS ONE, 2008, 3, e3179.	1.1	142
80	Identification of Angiogenesis/Metastases Genes Predicting Chemoradiotherapy Response in Patients With Laryngopharyngeal Carcinoma. Journal of Clinical Oncology, 2007, 25, 1369-1376.	0.8	37
81	Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2007, 13, 170-181.	3.2	118
82	Gene Expression Profiling of Liposarcoma Identifies Distinct Biological Types/Subtypes and Potential Therapeutic Targets in Well-Differentiated and Dedifferentiated Liposarcoma. Cancer Research, 2007, 67, 6626-6636.	0.4	217
83	A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing. Cell, 2007, 129, 1401-1414.	13.5	3,390
84	Genomic and Proteomic Profiles Reveal the Association of Gelsolin to TP53 Status and Bladder Cancer Progression. American Journal of Pathology, 2007, 171, 1650-1658.	1.9	30
85	A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer. Clinical Cancer Research, 2007, 13, 3215-3220.	3.2	54
86	Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nature Medicine, 2007, 13, 642-648.	15.2	297
87	The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nature Medicine, 2007, 13, 748-753.	15.2	275
88	Directed Differentiation and Transplantation of Human Embryonic Stem Cell-Derived Motoneurons. Stem Cells, 2007, 25, 1931-1939.	1.4	316
89	Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. Journal of Clinical Investigation, 2007, 117, 3248-3257.	3.9	167
90	Profiling Bladder Cancer Using Targeted Antibody Arrays. American Journal of Pathology, 2006, 168, 93-103.	1.9	162

#	Article	IF	Citations
91	Gene expression in ductus arteriosus and aorta: comparison of birth and oxygen effects. Physiological Genomics, 2006, 25, 250-262.	1.0	52
92	Defining Molecular Profiles of Poor Outcome in Patients With Invasive Bladder Cancer Using Oligonucleotide Microarrays. Journal of Clinical Oncology, 2006, 24, 778-789.	0.8	513
93	Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12843-12848.	3.3	105
94	Gene Expression Profiling Allows Distinction between Primary and Metastatic Squamous Cell Carcinomas in the Lung. Cancer Research, 2005, 65, 3063-3071.	0.4	132
95	Derivation of Multipotent Mesenchymal Precursors from Human Embryonic Stem Cells. PLoS Medicine, 2005, 2, e161.	3.9	396
96	The Absence of p53 Promotes Metastasis in a Novel Somatic Mouse Model for Hepatocellular Carcinoma. Molecular and Cellular Biology, 2005, 25, 1228-1237.	1.1	113
97	Nonequilibrium Raftlike Membrane Domains under Continuous Recycling. Physical Review Letters, 2005, 95, 168301.	2.9	128
98	Indirect measurements of differential gene expression with cDNA microarrays. BioTechniques, 2004, 36, 310-314.	0.8	8
99	Genome-Wide Profiling of Papillary Thyroid Cancer Identifies MUC1 as an Independent Prognostic Marker. Cancer Research, 2004, 64, 3780-3789.	0.4	137
100	Transformation fingerprint: induced STAT3-C, v-Src and Ha-Ras cause small initial changes but similar established profiles in mRNA. Oncogene, 2004, 23, 8455-8463.	2.6	23
101	Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site. Clinical Cancer Research, 2004, 10, 3282-3290.	3.2	194
102	Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. Journal of Clinical Investigation, 2004, 113, 414-424.	3.9	158
103	Gene Discovery in Bladder Cancer Progression using cDNA Microarrays. American Journal of Pathology, 2003, 163, 505-516.	1.9	177
104	Oncogenic Ras and Akt Signaling Contribute to Glioblastoma Formation by Differential Recruitment of Existing mRNAs to Polysomes. Molecular Cell, 2003, 12, 889-901.	4.5	387
105	Cytokine-induced Patterns of Gene Expression in Skeletal Muscle Tissue. Journal of Biological Chemistry, 2003, 278, 32324-32334.	1.6	13
106	Specific and Nonspecific Collapse in Protein Folding Funnels. Physical Review Letters, 2002, 88, 168101.	2.9	41
107	Role for Stearoyl-CoA Desaturase-1 in Leptin-Mediated Weight Loss. Science, 2002, 297, 240-243.	6.0	790
108	Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Research, 2002, 62, 6973-80.	0.4	144

#	Article	IF	CITATIONS
109	Distinct Transcriptional Profiles of Adipogenesisin Vivo and in Vitro. Journal of Biological Chemistry, 2001, 276, 34167-34174.	1.6	338
110	Weighted Neighbor Joining: A Likelihood-Based Approach to Distance-Based Phylogeny Reconstruction. Molecular Biology and Evolution, 2000, 17, 189-197.	3.5	417
111	The energy landscape theory of protein folding: Insights into folding mechanisms and scenarios. Advances in Protein Chemistry, 2000, 53, 87-152.	4.4	215
112	Exploring the protein folding funnel landscape. Physica D: Nonlinear Phenomena, 1997, 107, 366-382.	1.3	17
113	Protein folding funnels: the nature of the transition state ensemble. Folding & Design, 1996, 1, 441-450.	4.5	304
114	Funnels, pathways, and the energy landscape of protein folding: A synthesis. Proteins: Structure, Function and Bioinformatics, 1995, 21, 167-195.	1.5	2,415
115	Kinetic and thermodynamic analysis of proteinlike heteropolymers: Monte Carlo histogram technique. Journal of Chemical Physics, 1995, 103, 4732-4744.	1.2	187
116	Folding kinetics of proteinlike heteropolymers. Journal of Chemical Physics, 1994, 101, 1519-1528.	1.2	311
117	Properties and origins of protein secondary structure. Physical Review E, 1994, 49, 3440-3443.	0.8	51